By this... you mean being a part owner of the next standard of care for brain cancer suffers - then yes this is all there is... and this is what we want and why I’m here - given the landscape hasn’t changed in 20+ years and we perform considerably better than TMZ - the standard of care for years then this should be enough.
there has been a placement and there is an SPP - so anyone who wants more at .40 can get them and sit alongside the sophisticated investors... I think this is a prudent move - it’s not a $50 million raise with worthless options attached... its a real and reasonable amount for where we are at.
after the last set of results on a combined 30 cohort and for where we are at in the trial cycle and entering GBM Agile with other trials reporting data this year - I’ll happily buy more at .40 cents in this round.
